Circulating tumour cells for early detection of clinically relevant cancer
Standard
Circulating tumour cells for early detection of clinically relevant cancer. / Lawrence, Rachel; Watters, Melissa; Davies, Caitlin R; Pantel, Klaus; Lu, Yong-Jie.
In: NAT REV CLIN ONCOL, Vol. 20, No. 7, 07.2023, p. 487-500.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Circulating tumour cells for early detection of clinically relevant cancer
AU - Lawrence, Rachel
AU - Watters, Melissa
AU - Davies, Caitlin R
AU - Pantel, Klaus
AU - Lu, Yong-Jie
N1 - © 2023. Springer Nature Limited.
PY - 2023/7
Y1 - 2023/7
N2 - Given that cancer mortality is usually a result of late diagnosis, efforts in the field of early detection are paramount to reducing cancer-related deaths and improving patient outcomes. Increasing evidence indicates that metastasis is an early event in patients with aggressive cancers, often occurring even before primary lesions are clinically detectable. Metastases are usually formed from cancer cells that spread to distant non-malignant tissues via the blood circulation, termed circulating tumour cells (CTCs). CTCs have been detected in patients with early stage cancers and, owing to their association with metastasis, might indicate the presence of aggressive disease, thus providing a possible means to expedite diagnosis and treatment initiation for such patients while avoiding overdiagnosis and overtreatment of those with slow-growing, indolent tumours. The utility of CTCs as an early diagnostic tool has been investigated, although further improvements in the efficiency of CTC detection are required. In this Perspective, we discuss the clinical significance of early haematogenous dissemination of cancer cells, the potential of CTCs to facilitate early detection of clinically relevant cancers, and the technological advances that might improve CTC capture and, thus, diagnostic performance in this setting.
AB - Given that cancer mortality is usually a result of late diagnosis, efforts in the field of early detection are paramount to reducing cancer-related deaths and improving patient outcomes. Increasing evidence indicates that metastasis is an early event in patients with aggressive cancers, often occurring even before primary lesions are clinically detectable. Metastases are usually formed from cancer cells that spread to distant non-malignant tissues via the blood circulation, termed circulating tumour cells (CTCs). CTCs have been detected in patients with early stage cancers and, owing to their association with metastasis, might indicate the presence of aggressive disease, thus providing a possible means to expedite diagnosis and treatment initiation for such patients while avoiding overdiagnosis and overtreatment of those with slow-growing, indolent tumours. The utility of CTCs as an early diagnostic tool has been investigated, although further improvements in the efficiency of CTC detection are required. In this Perspective, we discuss the clinical significance of early haematogenous dissemination of cancer cells, the potential of CTCs to facilitate early detection of clinically relevant cancers, and the technological advances that might improve CTC capture and, thus, diagnostic performance in this setting.
KW - Humans
KW - Neoplastic Cells, Circulating/pathology
KW - Neoplasms/diagnosis
U2 - 10.1038/s41571-023-00781-y
DO - 10.1038/s41571-023-00781-y
M3 - SCORING: Review article
C2 - 37268719
VL - 20
SP - 487
EP - 500
JO - NAT REV CLIN ONCOL
JF - NAT REV CLIN ONCOL
SN - 1759-4774
IS - 7
ER -
